Korro Bio Inc (KRRO)

$6.07 -0.43 (-6.62%)
Market Cap 61.04M
Revenue (ttm) 2.27M
Net Income (ttm) -83.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,681.94%
Debt to Equity Ratio 0.00
Volume 2,064,100
Avg Vol 495,798
Day's Range N/A - N/A
Shares Out 9.39M
Stochastic %K 1%
Beta 2.94
Analysts Sell
Price Target $85.75

Company Profile

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The c...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 468 1999
Address:
One Kendall Square, Building 600-700 Suite 6-401, Cambridge, United States
MimicLB
MimicLB Nov. 14 at 10:22 PM
$KRRO please for the god sake, remember the whole crispr, ipsc, nk, cart drama ?adar is the same pos, pull your money out and go buy some NVDA or something like SP500 or Dow Jones index.
1 · Reply
AmumuLB
AmumuLB Nov. 14 at 10:21 PM
$KRRO please for the god sake, remember the whole crispr, ipsc, nk, cart drama ?adar is the same pos, pull your money out and go buy some NVDA
0 · Reply
TradeOrGoHome
TradeOrGoHome Nov. 14 at 9:52 PM
$KRRO added more
0 · Reply
MimicLB
MimicLB Nov. 14 at 9:34 PM
$KRRO they have no viable asset, it will become a penny stock, i mean when it is a penny stock, it can go up 100-200% in a month, so play this when it is around 0.5-0.6 dollar a share. and sell around 1 dollars.
1 · Reply
Astrid00
Astrid00 Nov. 14 at 7:59 PM
$KRRO will rebound
0 · Reply
WayneSmith
WayneSmith Nov. 14 at 7:53 PM
$KRRO $IBTA The market has officially entered a bull market track.
0 · Reply
WayneSmith
WayneSmith Nov. 14 at 7:41 PM
$KRRO $AVXL A strong breakout has ushered in a new era for the bulls.
1 · Reply
bellamyRandolph33
bellamyRandolph33 Nov. 14 at 7:34 PM
$KRRO I’m staying long NXXT into a potential report today because institutions see intrinsic value above the tag and this is the last quiet window before a rerate and Barclays filed 32,840 ≈ $65.7K while Forefront holds 501,000 ≈ $1.00M
0 · Reply
Crypto9999
Crypto9999 Nov. 14 at 7:25 PM
$KRRO Shares outstanding is 9,390,000 From SimplyWallSt: assets of ~$161.6 M, liabilities ~$62.5 M giving shareholders’ equity ~$99.0 M. They note zero debt (i.e., debt-to‐equity ratio ~0%). per share roughly $10.54 What am i missing???
0 · Reply
US_Bull
US_Bull Nov. 14 at 6:28 PM
$KRRO Already up 5% on those 6k shares bought PM. Continuation next week I see double digits before EOY. Stock is just way oversold.
0 · Reply
Latest News on KRRO
Korro Bio Early Trial Results Fall Short; Stock Hits New Low

Nov 13, 2025, 2:26 PM EST - 1 day ago

Korro Bio Early Trial Results Fall Short; Stock Hits New Low

This biotech is halting its work with Novo Nordisk and laying off more people

Nov 12, 2025, 5:59 PM EST - 2 days ago

This biotech is halting its work with Novo Nordisk and laying off more people

Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs

Nov 12, 2025, 4:05 PM EST - 2 days ago

Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs

Korro to Participate in Upcoming Investor and Scientific Conferences

Sep 2, 2025, 4:30 PM EDT - 2 months ago

Korro to Participate in Upcoming Investor and Scientific Conferences

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 12, 2025, 7:00 AM EDT - 3 months ago

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

Jul 21, 2025, 8:00 AM EDT - 4 months ago

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

Korro to Participate in Upcoming Investor Conferences

May 14, 2025, 4:05 PM EDT - 6 months ago

Korro to Participate in Upcoming Investor Conferences

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025, 4:30 PM EDT - 6 months ago

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

Apr 1, 2025, 7:30 AM EDT - 8 months ago

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

Mar 18, 2025, 7:00 AM EDT - 8 months ago

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

Mar 14, 2025, 8:00 AM EDT - 8 months ago

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

Korro to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 9 months ago

Korro to Present at the TD Cowen 45th Annual Health Care Conference

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Nov 21, 2024, 7:30 AM EST - 1 year ago

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Korro to Present at the Jefferies London Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

Korro to Present at the Jefferies London Healthcare Conference

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

Nov 4, 2024, 7:25 AM EST - 1 year ago

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Korro to Participate in Upcoming September Investor and Scientific Conferences

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Korro to Participate in Upcoming September Investor and Scientific Conferences

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

Korro to Participate in Upcoming June Investor and Scientific Conferences

May 30, 2024, 4:01 PM EDT - 1 year ago

Korro to Participate in Upcoming June Investor and Scientific Conferences

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

May 20, 2024, 2:30 PM EDT - 1 year ago

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

May 14, 2024, 4:01 PM EDT - 1 year ago

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

Korro Announces $70 Million Private Placement

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Korro Announces $70 Million Private Placement

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

Mar 26, 2024, 4:01 PM EDT - 1 year ago

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

Mar 14, 2024, 5:34 PM EDT - 1 year ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRYS MREO TAK WVE

Korro to Present at the TD Cowen 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 1 year ago

Korro to Present at the TD Cowen 44th Annual Health Care Conference

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

Jan 18, 2024, 8:00 AM EST - 1 year ago

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 8:00 AM EST - 2 years ago

Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Dec 7, 2023, 8:00 AM EST - 2 years ago

Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Korro Bio Appoints Dr. Rachel Meyers to Board of Directors

Nov 28, 2023, 8:00 AM EST - 2 years ago

Korro Bio Appoints Dr. Rachel Meyers to Board of Directors

UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Nov 3, 2023, 3:31 PM EDT - 2 years ago

UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Nov 3, 2023, 12:19 PM EDT - 2 years ago

Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ

Oct 6, 2023, 2:14 PM EDT - 2 years ago

FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ

Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results

Aug 10, 2023, 4:01 PM EDT - 2 years ago

Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results

Korro Bio and Frequency Therapeutics Announce Merger Agreement

Jul 14, 2023, 6:30 AM EDT - 2 years ago

Korro Bio and Frequency Therapeutics Announce Merger Agreement

Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results

May 12, 2023, 4:01 PM EDT - 2 years ago

Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results

Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results

Mar 10, 2023, 7:30 AM EST - 2 years ago

Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results

Frequency Therapeutics to Participate at Upcoming March Investor Conferences

Feb 27, 2023, 7:30 AM EST - 2 years ago

Frequency Therapeutics to Participate at Upcoming March Investor Conferences

Small Animal Imaging In Vivo Market is Anticipated to Reach a Value of USD 6.1 Billion by Growing at a CAGR of 8.89% During 2022-2028; Expanding Healthcare Sector and Rising Clinical Research to Elevate Market Growth

Feb 23, 2023, 7:45 AM EST - 2 years ago

Small Animal Imaging In Vivo Market is Anticipated to Reach a Value of USD 6.1 Billion by Growing at a CAGR of 8.89% During 2022-2028; Expanding Healthcare Sector and Rising Clinical Research to Elevate Market Growth

Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Feb 13, 2023, 8:05 AM EST - 2 years ago

Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program

Dec 19, 2022, 7:30 AM EST - 3 years ago

Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company's Second Therapeutic Candidate for Sensorineural Hearing Loss

Dec 15, 2022, 7:30 AM EST - 3 years ago

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company's Second Therapeutic Candidate for Sensorineural Hearing Loss

Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results

Nov 17, 2022, 7:30 AM EST - 3 years ago

Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results

Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results

Nov 8, 2022, 4:05 PM EST - 3 years ago

Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results

Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Oct 12, 2022, 7:30 AM EDT - 3 years ago

Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Frequency Therapeutics to Participate in September Investor and Medical Conferences

Aug 30, 2022, 7:30 AM EDT - 3 years ago

Frequency Therapeutics to Participate in September Investor and Medical Conferences

Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results

Aug 9, 2022, 4:05 PM EDT - 3 years ago

Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results

Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference

May 18, 2022, 7:30 AM EDT - 3 years ago

Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference

MimicLB
MimicLB Nov. 14 at 10:22 PM
$KRRO please for the god sake, remember the whole crispr, ipsc, nk, cart drama ?adar is the same pos, pull your money out and go buy some NVDA or something like SP500 or Dow Jones index.
1 · Reply
AmumuLB
AmumuLB Nov. 14 at 10:21 PM
$KRRO please for the god sake, remember the whole crispr, ipsc, nk, cart drama ?adar is the same pos, pull your money out and go buy some NVDA
0 · Reply
TradeOrGoHome
TradeOrGoHome Nov. 14 at 9:52 PM
$KRRO added more
0 · Reply
MimicLB
MimicLB Nov. 14 at 9:34 PM
$KRRO they have no viable asset, it will become a penny stock, i mean when it is a penny stock, it can go up 100-200% in a month, so play this when it is around 0.5-0.6 dollar a share. and sell around 1 dollars.
1 · Reply
Astrid00
Astrid00 Nov. 14 at 7:59 PM
$KRRO will rebound
0 · Reply
WayneSmith
WayneSmith Nov. 14 at 7:53 PM
$KRRO $IBTA The market has officially entered a bull market track.
0 · Reply
WayneSmith
WayneSmith Nov. 14 at 7:41 PM
$KRRO $AVXL A strong breakout has ushered in a new era for the bulls.
1 · Reply
bellamyRandolph33
bellamyRandolph33 Nov. 14 at 7:34 PM
$KRRO I’m staying long NXXT into a potential report today because institutions see intrinsic value above the tag and this is the last quiet window before a rerate and Barclays filed 32,840 ≈ $65.7K while Forefront holds 501,000 ≈ $1.00M
0 · Reply
Crypto9999
Crypto9999 Nov. 14 at 7:25 PM
$KRRO Shares outstanding is 9,390,000 From SimplyWallSt: assets of ~$161.6 M, liabilities ~$62.5 M giving shareholders’ equity ~$99.0 M. They note zero debt (i.e., debt-to‐equity ratio ~0%). per share roughly $10.54 What am i missing???
0 · Reply
US_Bull
US_Bull Nov. 14 at 6:28 PM
$KRRO Already up 5% on those 6k shares bought PM. Continuation next week I see double digits before EOY. Stock is just way oversold.
0 · Reply
US_Bull
US_Bull Nov. 14 at 6:27 PM
$KRRO Easy $.
0 · Reply
Steve_TheBull_Rogers
Steve_TheBull_Rogers Nov. 14 at 6:14 PM
$KRRO 1 more day of the 3 day dead rule So Monday into Tues should see the hard bounce
1 · Reply
idave
idave Nov. 14 at 5:59 PM
$KRRO 3 day rule looking pretty good here. Expect a bounce coming.
0 · Reply
Astrid00
Astrid00 Nov. 14 at 5:50 PM
$KRRO 🍀
0 · Reply
Tradebub
Tradebub Nov. 14 at 5:14 PM
$KRRO $8.00 may still be doable. They have lots of cash and some intrinsic value.
0 · Reply
Rick2058
Rick2058 Nov. 14 at 4:55 PM
$KRRO Looks like an over-reaction. Added for rebound. https://www.stocktitan.net/news/KRRO/korro-reports-third-quarter-financial-results-provides-updates-on-xyg3i0v05oew.html
0 · Reply
Newcar
Newcar Nov. 14 at 4:46 PM
$KRRO Excuse me, but wasn't there a failure of the therapy? How can it still be so high? Waiting 3$.
1 · Reply
Tradebub
Tradebub Nov. 14 at 4:06 PM
$KRRO Amazingly flat!
0 · Reply
Zackpedia
Zackpedia Nov. 14 at 3:57 PM
$KRRO 5.7 support and now it’s up again
0 · Reply
resistancebreakers
resistancebreakers Nov. 14 at 3:51 PM
$KRRO $PN
0 · Reply
HollowLiquidity
HollowLiquidity Nov. 14 at 3:10 PM
$KRRO I’ve seen small caps with dreams. NXXT has data. $65.8M revenue YTD. +5% MoM growth. Massive 300-acre energy+AI project. 48 funds aren’t guessing — they know what $2 turns into when the market stops sleeping. And earnings? Drop today.
0 · Reply
Struin
Struin Nov. 14 at 3:08 PM
$KRRO 12 dollar company ashaming price this
0 · Reply